Navigation Links
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Date:2/11/2013

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188.  

Brian M. Culley , Chief Executive Officer, said: "Consistent with our guidance from October 2011 and our commitment to FDA, we have initiated this study before the end of the first quarter.  We were pleased with the discussion we had with the Agency on the study protocol and our agreement on the supra-therapeutic dose." 

Santosh Vetticaden, Chief Medical Officer, said: "The FDA requires an assessment of cardiac repolarization for most new drugs having systemic bioavailability. This study will assess whether or not ANX-188 has an effect on QT prolongation. The study should complete dosing in the first quarter, and we expect to announce results in the second quarter of 2013."

The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers.  The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial.  Sixty subjects will be enrolled.  Each subject will receive each of four treatments (placebo, active control, ANX-188 therapeutic dose, ANX-188 supra-therapeutic dose) during each of the four treatment periods.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions.  The C
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Establishment of Regulatory Advisory Board
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
5. Applied Genetics Initiates Commercial Operation
6. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
10. Positive Clinical Study Results for BSPs HyperQ Technology
11. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Investor-Edge has initiated coverage on ... Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. ... MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free ... http://investor-edge.com/register . On Wednesday, October 29, ... the Dow Jones Industrial Average declined 0.18%, to finish ...
(Date:10/30/2014)... UK (PRWEB) October 29, 2014 Global ... of the world economic crisis during 2008-2009, especially in ... has recovered and currently is keeping to a growing ... output volume is utilized in the construction segment. In ... of pipes, profiles, tubing, sheets and rigid film. Moreover, ...
(Date:10/30/2014)... On October 26th at the Mid ... leading applied stem cell research scientist Neil Riordan, ... talks on New Techniques for Enhancing Stem Cell ... Cells. , Dr. Riordan focused on historical medical ... AlphaGEMS that include: wound healing; inflammation and pain ...
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Rancho BioSciences Manually Curated TCGA Data Sets Available 2
... leading innovator in the development and commercialization of sensing systems ... (CBRNE) materials, today announced a media awareness initiative for JMAR,s ... online system for real-time detection of pathogens in water. ... ...
... release of GridGain 2.1 - the next version of its innovative ... ... January 13, 2009 -- GridGain Systems is proud to ... its innovative Java-based Open Cloud Platform. GridGain 2.1 provides the industry ...
... Coronary StentForms Alliance to Jointly Develop Drug Eluting ... announced today that that the company entered into ... incorporated subsidiary of Opto Circuits (OCI) Ltd., by ... Maxcor,s Genius MAGIC Cobalt Chromium Coronary Stent System ...
Cached Biology Technology:JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 2JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 3JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 4GridGain 2.1 - Open Cloud Platform Enables Development of Native Cloud Applications 2GridGain 2.1 - Open Cloud Platform Enables Development of Native Cloud Applications 3Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons 2Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons 3
(Date:10/31/2014)... in cities is good for attracting species, but it may ... University of Iowa study has found. , The researchers surveyed ... and recorded the abundance of two insects that interact with ... trees, black cherry and black walnut, they didn,t find a ... that feed on the walnuts and black cherries and a ...
(Date:10/31/2014)... been studying the behavior of approximately 300 wild ... They observed that ravens slowly build alliances through ... they also observed that these affiliative interactions were ... about 50 % of the cases these interventions ... ravens, intervening can be potentially risky when the ...
(Date:10/30/2014)... LANSING, Mich. – When most animals begin life, cells ... or a vital organ. However, mammals, including humans, are ... a different first choice – to become the protective ... It,s during this critical first step that research from ... published in the current issue of PLOS ...
Breaking Biology News(10 mins):Green spaces don't ensure biodiversity in urban areas 2Identifying the source of stem cells 2
... Nelson Laboratories ( www.nelsonlabs.com ) will offer free ... in San Jose, CA ... Those interested in a consultation should register at ... Rollins will also present, "Selection, Testing and Validation ...
... Wilhoit and Timothy Coolong from the University of Kentucky ... application of organic mulches more efficient. The research team ... in the August issue of HortTechnology . The ... to document its efficiency. "We modified an unroller so ...
... Why do crosses between closely related species fail to ... Axel Imhof of Ludwig-Maximilians-Universitaet (LMU) in Munich shows that ... - of certain key proteins are crucial in mediating ... to the same biological species, if matings between them ...
Cached Biology News:Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose 2New bale unroller design deemed effective 2Origin of species: Protein imbalances doom hybrids 2
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
... DAPI (4,6-diamidine-2-phenylindole, dihydrochloride) is a ... nucleus blue in color. The ... contrast to red fluorochromes such ... or R-Phycoerythrin. DAPI can be ...
... (CYP450) metabolite postulated to play an autacoid ... In rat cerebral microvessels, 20-HETE is a ... is excreted mainly as the glucuronide conjugate. ... in human urine) is about 10-fold lower ...
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
Biology Products: